Literature DB >> 9794903

Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial.

G D'Amico1, F Politi, A Morabito, A D'Antoni, D Guerrera, G Giannuoli, M Traina, G Vizzini, L Pasta, L Pagliaro.   

Abstract

beta-Blockers and sclerotherapy prevent long-term upper digestive rebleeding in cirrhosis but they seem ineffective for early rebleeding. We compared octreotide with a placebo for the prevention of early rebleeding in cirrhotic patients. After control of acute upper digestive bleeding, 262 consecutive cirrhotic patients were randomized to octreotide 100 microgram subcutaneously three times a day for 15 days (n = 131) or to the placebo (n = 131), in a double blind pragmatic trial in which beta-blockers and/or sclerotherapy were allowed together with the experimental treatment. Separate randomization and analysis were performed according to whether patients were eligible for beta-blockers and/or sclerotherapy (101 placebo, 97 octreotide) or not (30 placebo, 34 octreotide). Rebleeding within 15 days was the primary measure of treatment efficacy; 6-week rebleeding rate was also assessed as a secondary measure. Fifteen-day cumulative proportions of patients rebleeding were 28% in the placebo group and 24% in the octreotide group (P = .40); corresponding figures among the 198 patients eligible to beta-blockers and/or sclerotherapy were 26% and 16% (P = .05) and among the 64 not eligible for these treatments 33% and 49% (P = .29). Among patients eligible to beta-blockers and/or sclerotherapy, a significant reduction of rebleeding episodes (35 vs. 18, P = .03), blood transfusions (75 vs. 50, P = .04), and days of stay in hospital (1,544 vs. 1,190, P = .0001) was also found in the octreotide group: this beneficial effect was confirmed 6 weeks after randomization. Mortality was not affected by octreotide in either group of patients. It is suggested that octreotide may reduce the risk of early rebleeding in cirrhotic patients treated with beta-blockers and/or sclerotherapy after control of acute upper digestive bleeding. Further studies are needed to confirm this result.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794903     DOI: 10.1002/hep.510280507

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

Review 1.  Pharmacologic therapy for portal hypertension.

Authors:  R C Lowe; N D Grace
Journal:  Curr Gastroenterol Rep       Date:  2001-02

2.  Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis.

Authors:  Borko Nojkov; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Effects of octreotide on intestinal transit and bacterial translocation in conscious rats with portal hypertension and liver fibrosis.

Authors:  N Veal; H Auduberteau; C Lemarie; F Oberti; P Calès
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

4.  Treatment of Variceal Bleeding.

Authors:  Joseph J. Y. Sung
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

Review 5.  Current management of portal hypertension.

Authors:  Andrew S Wright; Layton F Rikkers
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

6.  Variceal Hemorrhage.

Authors:  Lisa A. Brandenburger; Fredric G. Regenstein
Journal:  Curr Treat Options Gastroenterol       Date:  2002-02

7.  48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.

Authors:  D Ludwig; S Schädel; A Brüning; B Schiefer; E F Stange
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

Review 8.  Somatostatin analogues for acute bleeding oesophageal varices.

Authors:  Peter C Gøtzsche; Asbjørn Hróbjartsson
Journal:  Cochrane Database Syst Rev       Date:  2008-07-16

9.  Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.

Authors:  Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

10.  Prevention and management of variceal hemorrhage.

Authors:  Dong Hyun Kim; Jun Yong Park
Journal:  Int J Hepatol       Date:  2013-03-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.